Research analysts at Stifel Nicolaus started coverage on shares of GlycoMimetics (NASDAQ:CBIO – Get Free Report) in a report issued on Wednesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $28.00 price target on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 85.92% from the stock’s current price.
Other research analysts also recently issued reports about the stock. TD Cowen upgraded shares of GlycoMimetics to a “strong-buy” rating in a research report on Friday, June 20th. Lifesci Capital upgraded GlycoMimetics to a “strong-buy” rating and set a $22.00 price target on the stock in a research note on Wednesday, June 18th.
GlycoMimetics Stock Performance
About GlycoMimetics
Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Read More
- Five stocks we like better than GlycoMimetics
- CD Calculator: Certificate of Deposit Calculator
- AST SpaceMobile’s Signal Strengthens as Stock Nears Orbit
- What is an Earnings Surprise?
- Cybersecurity Confidence: 3 of the Market’s Most Upgraded Stocks
- Most Volatile Stocks, What Investors Need to Know
- Costco at a Crossroads: Is the Next Move Higher or Lower?
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.
